Vimarsana
Biggest News Aggregation in the World

Page 13 - Sarepta News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Sarepta. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Sarepta Today - Breaking & Trending Today

Earnings Scheduled For November 1, 2023 - Qualcomm (NASDAQ:QCOM), QuidelOrtho (NASDAQ:QDEL) - Vimarsana News

Earnings Scheduled For November 1, 2023 - Qualcomm (NASDAQ:QCOM), QuidelOrtho (NASDAQ:QDEL)

Companies Reporting Before The Bell • GSK (NYSE:GSK) is expected to report quarterly earnings at $1.07 per share on revenue of $9.37 billion.

Govt set to file progress report on talks with makers of rare disease drugs - Vimarsana News

Govt set to file progress report on talks with makers of rare disease drugs

Activists have demanded that tax exemption be given for such drugs that are approved by Indias drug regulator and are available in the country. During the last hearing, the government counsel informed the court it has flagged the issue over customs duty and GST to the finance ministry and “is hopeful of informing the court about the outcome of the said issue on the next date”.

11 Best Long-term Stocks To Buy For High Returns - Vimarsana News

11 Best Long-term Stocks To Buy For High Returns

In this piece, we will take a look at the 11 best long term stocks to buy for high returns. If you want to skip our introduction to the current drivers of stock market performance, then check out 5 Best Long-term Stocks To Buy For High Returns. The stock market is made up of thousands […]

Source: yahoo.com
11 Best Long-term Stocks To Buy For High Returns - Vimarsana News

11 Best Long-term Stocks To Buy For High Returns

In this piece, we will take a look at the 11 best long term stocks to buy for high returns.

Most of today's gene therapies rely on viruses — and that's a problem - Vimarsana News

Most of today's gene therapies rely on viruses — and that's a problem

The next big strides in gene therapy for rare diseases may come from CRISPR and new approaches to delivery.